BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28295216)

  • 1. Genetic alterations in TRAF3 and CYLD that regulate nuclear factor κB and interferon signaling define head and neck cancer subsets harboring human papillomavirus.
    Chen T; Zhang J; Chen Z; Van Waes C
    Cancer; 2017 May; 123(10):1695-1698. PubMed ID: 28295216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma.
    Hajek M; Sewell A; Kaech S; Burtness B; Yarbrough WG; Issaeva N
    Cancer; 2017 May; 123(10):1778-1790. PubMed ID: 28295222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NF-κB over-activation portends improved outcomes in HPV-associated head and neck cancer.
    Schrank TP; Prince AC; Sathe T; Wang X; Liu X; Alzhanov DT; Burtness B; Baldwin AS; Yarbrough WG; Issaeva N
    Oncotarget; 2022; 13():707-722. PubMed ID: 35634245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuated TRAF3 Fosters Activation of Alternative NF-κB and Reduced Expression of Antiviral Interferon, TP53, and RB to Promote HPV-Positive Head and Neck Cancers.
    Zhang J; Chen T; Yang X; Cheng H; Späth SS; Clavijo PE; Chen J; Silvin C; Issaeva N; Su X; Yarbrough WG; Annunziata CM; Chen Z; Van Waes C
    Cancer Res; 2018 Aug; 78(16):4613-4626. PubMed ID: 29921694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRAF3 and NBR1 both influence the effect of the disease-causing CYLD(Arg936X) mutation on NF-κB activity.
    Danis J; Kelemen E; Rajan N; Nagy N; Széll M; Ádám É
    Exp Dermatol; 2021 Nov; 30(11):1705-1710. PubMed ID: 33999445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYLD Alterations in the Tumorigenesis and Progression of Human Papillomavirus-Associated Head and Neck Cancers.
    Cui Z; Kang H; Grandis JR; Johnson DE
    Mol Cancer Res; 2021 Jan; 19(1):14-24. PubMed ID: 32883697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noncanonical HPV carcinogenesis drives radiosensitization of head and neck tumors.
    Schrank TP; Kothari A; Weir WH; Stepp WH; Rehmani H; Liu X; Wang X; Sewell A; Li X; Tasoulas J; Kim S; Yarbrough G; Xie Y; Flamand Y; Marur S; Hayward MC; Wu D; Burtness B; Anderson KS; Baldwin AS; Yarbrough WG; Issaeva N
    Proc Natl Acad Sci U S A; 2023 Aug; 120(32):e2216532120. PubMed ID: 37523561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.
    Annunziata CM; Davis RE; Demchenko Y; Bellamy W; Gabrea A; Zhan F; Lenz G; Hanamura I; Wright G; Xiao W; Dave S; Hurt EM; Tan B; Zhao H; Stephens O; Santra M; Williams DR; Dang L; Barlogie B; Shaughnessy JD; Kuehl WM; Staudt LM
    Cancer Cell; 2007 Aug; 12(2):115-30. PubMed ID: 17692804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations.
    Li YY; Chung GT; Lui VW; To KF; Ma BB; Chow C; Woo JK; Yip KY; Seo J; Hui EP; Mak MK; Rusan M; Chau NG; Or YY; Law MH; Law PP; Liu ZW; Ngan HL; Hau PM; Verhoeft KR; Poon PH; Yoo SK; Shin JY; Lee SD; Lun SW; Jia L; Chan AW; Chan JY; Lai PB; Fung CY; Hung ST; Wang L; Chang AM; Chiosea SI; Hedberg ML; Tsao SW; van Hasselt AC; Chan AT; Grandis JR; Hammerman PS; Lo KW
    Nat Commun; 2017 Jan; 8():14121. PubMed ID: 28098136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subquinocin, a small molecule inhibitor of CYLD and USP-family deubiquitinating enzymes, promotes NF-κB signaling.
    Yamanaka S; Sato Y; Oikawa D; Goto E; Fukai S; Tokunaga F; Takahashi H; Sawasaki T
    Biochem Biophys Res Commun; 2020 Mar; 524(1):1-7. PubMed ID: 31898971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of CYLD and NF-kappaB in human cholesteatoma epithelium.
    Byun JY; Yune TY; Lee JY; Yeo SG; Park MS
    Mediators Inflamm; 2010; 2010():796315. PubMed ID: 20414373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYLD suppression enhances the pro-inflammatory effects and hyperproliferation of rheumatoid arthritis fibroblast-like synoviocytes by enhancing NF-κB activation.
    Zhang LM; Zhou JJ; Luo CL
    Arthritis Res Ther; 2018 Oct; 20(1):219. PubMed ID: 30285829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of CYLD downregulation in breast cancer.
    Hayashi M; Jono H; Shinriki S; Nakamura T; Guo J; Sueta A; Tomiguchi M; Fujiwara S; Yamamoto-Ibusuki M; Murakami K; Yamashita S; Yamamoto Y; Li JD; Iwase H; Ando Y
    Breast Cancer Res Treat; 2014 Feb; 143(3):447-57. PubMed ID: 24398777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NF-kappaB is essential for induction of CYLD, the negative regulator of NF-kappaB: evidence for a novel inducible autoregulatory feedback pathway.
    Jono H; Lim JH; Chen LF; Xu H; Trompouki E; Pan ZK; Mosialos G; Li JD
    J Biol Chem; 2004 Aug; 279(35):36171-4. PubMed ID: 15226292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prion protein is required for tumor necrosis factor α (TNFα)-triggered nuclear factor κB (NF-κB) signaling and cytokine production.
    Wu GR; Mu TC; Gao ZX; Wang J; Sy MS; Li CY
    J Biol Chem; 2017 Nov; 292(46):18747-18759. PubMed ID: 28900035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The E3 ubiquitin ligase MIB2 enhances inflammation by degrading the deubiquitinating enzyme CYLD.
    Uematsu A; Kido K; Takahashi H; Takahashi C; Yanagihara Y; Saeki N; Yoshida S; Maekawa M; Honda M; Kai T; Shimizu K; Higashiyama S; Imai Y; Tokunaga F; Sawasaki T
    J Biol Chem; 2019 Sep; 294(38):14135-14148. PubMed ID: 31366726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
    Keats JJ; Fonseca R; Chesi M; Schop R; Baker A; Chng WJ; Van Wier S; Tiedemann R; Shi CX; Sebag M; Braggio E; Henry T; Zhu YX; Fogle H; Price-Troska T; Ahmann G; Mancini C; Brents LA; Kumar S; Greipp P; Dispenzieri A; Bryant B; Mulligan G; Bruhn L; Barrett M; Valdez R; Trent J; Stewart AK; Carpten J; Bergsagel PL
    Cancer Cell; 2007 Aug; 12(2):131-44. PubMed ID: 17692805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deubiquitinating activity of CYLD is impaired by SUMOylation in neuroblastoma cells.
    Kobayashi T; Masoumi KC; Massoumi R
    Oncogene; 2015 Apr; 34(17):2251-60. PubMed ID: 24909169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expanding CYLD protein in NF-κβ/TNF-α signaling pathway in response to Lactobacillus acidophilus in non-metastatic rectal cancer patients.
    Zamani F; Khalighfard S; Kalhori MR; Poorkhani A; Amiriani T; Hosseinzadeh P; Esmati E; Alemrajabi M; Nikoofar A; Safarnezhad Tameshkel F; Alizadeh AM
    Med Oncol; 2023 Sep; 40(10):302. PubMed ID: 37725175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pro-inflammatory role of deubiquitinating enzyme cylindromatosis (CYLD) in vascular smooth muscle cells.
    Liu S; Lv J; Han L; Ichikawa T; Wang W; Li S; Wang XL; Tang D; Cui T
    Biochem Biophys Res Commun; 2012 Mar; 420(1):78-83. PubMed ID: 22406061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.